D.E. Shaw & Co
SYRS

D.E. Shaw & Co’s Syros Pharmaceuticals, Inc. Common Stock SYRS Stock Holding History

D.E. Shaw & Co’s Portfolio SYRS Stock Details SYRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-12,181
Closed -$145K – 5860
2022
Q1 		$145K Buy
+12,181
New +$218K ﹤0.01% 4942
2021
Q2 		– Sell
-3,768
Closed -$282K – 5075
2021
Q1 		$282K Sell
3,768
-19,601
-84% -$2.04M ﹤0.01% 3736
2020
Q4 		$2.54M Buy
23,369
+4,251
+22% +$388K ﹤0.01% 2403
2020
Q3 		$1.69M Sell
19,118
-4,125
-18% -$469K ﹤0.01% 2513
2020
Q2 		$2.48M Buy
23,243
+14,761
+174% +$1.32M ﹤0.01% 2237
2020
Q1 		$503K Sell
8,482
-6,226
-42% -$422K ﹤0.01% 3205
2019
Q4 		$1.02M Buy
14,708
+7,414
+102% +$450K ﹤0.01% 2980
2019
Q3 		$757K Sell
7,294
-2,139
-23% -$202K ﹤0.01% 2986
2019
Q2 		$873K Sell
9,433
-1,836
-16% -$128K ﹤0.01% 2758
2019
Q1 		$1.03M Buy
11,269
+2,381
+27% +$166K ﹤0.01% 2595
2018
Q4 		$496K Buy
8,888
+7,859
+764% +$597K ﹤0.01% 3093
2018
Q3 		$123K Buy
+1,029
New +$119K ﹤0.01% 3606

Other funds holding SYRS

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
ABG
Ally Bridge Group New York $113M AUM 245.92% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

D.E. Shaw & Co's SYRS Position: Q2 2022 in Review

D.E. Shaw & Co sold out of Syros Pharmaceuticals, Inc. Common Stock (SYRS) in Q2 2022, closing a stake of 12,181 shares — an estimated $145K sold.

D.E. Shaw & Co first reported a position in SYRS in Q3 2018 and held it in 12 quarters. The position peaked at $2.54M in Q4 2020. 67 funds tracked by Wall St. Rank hold SYRS as of Q2 2022.

  • D.E. Shaw & Co reported no remaining Syros Pharmaceuticals, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • D.E. Shaw & Co sold 12,181 Syros Pharmaceuticals, Inc. Common Stock shares in Q2 2022, an estimated $145K.
  • D.E. Shaw & Co first reported a position in Syros Pharmaceuticals, Inc. Common Stock in Q3 2018 and held it in 12 quarters.
  • D.E. Shaw & Co's Syros Pharmaceuticals, Inc. Common Stock position peaked at $2.54M in Q4 2020.
  • 67 funds tracked by Wall St. Rank held Syros Pharmaceuticals, Inc. Common Stock as of Q2 2022.

Based on D.E. Shaw & Co's 13F filing for Q2 2022, filed 15 Aug 2022.